OWC PHARMACEUTICAL RESEARCH CORP. (OTCMKTS:OWCP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As part of the Registrant’s preparation for its Phase II efficacy study (the “Psoriasis Study”) of its cannabinoid-based ointment for the treatment of skin diseases, the Registrant appointed Professor Yuval Ramot as a consultant. Professor Ramot is the Head of the Psoriasis Clinic at Hadassah – Hebrew University Medical Center in Jerusalem, Israel (“Hadassah”) and specializes in Dermatology and Venereology. Professor Ramot holds an MD and an MSc degree in Biochemistry from the Hebrew University of Jerusalem, Israel. Following his medical training, he specialized in hair research in the Department of Dermatology at Lübeck University, Germany. In March 2016, he joined the Department of Dermatology at Hadassah and the Center for Genetic Diseases of the Skin and Hair, where he focuses on research of genetic skin and hair diseases and toxicology of the skin. His main clinical interest is in inflammatory diseases of the skin. He is the director of the psoriasis and hidradenitis suppurativa clinics at Hadassah. He is the recipient of the Minerva Post-doctoral Fellowship and the Young Dermatologist International Achievement Award. He has also co-authored 10 chapters in books and more than 135 articles in peer-reviewed journals.

On August 20, 2018, Ms. Hannah Feuer, a member of the Registrant’s board of directors and Chairperson of the Registrant’s audit committee, resigned as director and Chairperson of the audit committee, effective immediately. Ms. Feuer stated she was resigning all board of directors and committee memberships on which she currently serves as a condition of acceptance related to her expected appointment to a banking corporation. Ms. Feuer’s resignation is not the result of any disagreement with the policies, practices or procedures of the Registrant. Ms. Feuer’s letter of resignation is attached hereto as Exhibit 17.1.

(d) Exhibits

OWC Pharmaceutical Research Corp. Exhibit
EX-17.1 2 ex17-1.htm   August 20,…
To view the full exhibit click here

About OWC PHARMACEUTICAL RESEARCH CORP. (OTCMKTS:OWCP)

OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.